LORBRIQUA® (lorlatinib) is indicated for the treatment of adult patients with ALK+ metastatic NSCLC.1
AEs, adverse events; ALK, anaplastic lymphoma kinase; ALK+, anaplastic lymphoma kinase-positive; CNS, central nervous system; HR, hazard ratio; IC, intracranial; NSCLC, non-small cell lung cancer; PFS, progression-free survival; QoL, quality of life.
Please click the Prescribing Information link to view the safety and adverse events information of LORBRIQUA®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-LOR-IND-0129 June 2022
The Lung Cancer Foundation of America aims to improve the survivorship of patients with lung cancer through the funding of transformative science.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022